FDA Makes It 50 With Accord Trastuzumab Biosimilar Approval
Henlius-Partnered Hercessi Rival To Herceptin Becomes 50th US Biosimilar And First For Accord
The US FDA has marked a milestone with the approval of the country’s 50th biosimilar, in the form of Henlius and Accord BioPharma’s Hercessi trastuzumab rival to Herceptin.
